文献速递血栓与止血

全髋和膝关节置换患者静脉血栓栓塞预防方案的比较效果:一项网络荟萃分析

Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis.
PubMed 文献 · J Thromb Haemost · 2017-01-19

该网络荟萃分析汇总1990年1月至2016年6月发表的随机对照试验,同时比较12种静脉血栓栓塞预防方案相对于每日一次低分子量肝素(LMWH Low)的静脉血栓栓塞和出血风险。直接口服Xa抑制剂较LMWH Low总深静脉血栓风险更低(OR 0.45;95%CI 0.35-0.57),且未显著增加出血(OR 1.21;95%CI 0.79-1.90);维生素K拮抗剂(VKA)调整至INR 2-3者DVT事件更多(OR 1.56;95%CI 1.14-2.14)。

要点

  • 直接口服Xa抑制剂较低分子量肝素每日一次方案降低总DVT风险(OR 0.45;95%CI 0.35-0.57)。
  • 直接口服Xa抑制剂未导致显著更多出血(OR 1.21;95%CI 0.79-1.90)。
  • 维生素K拮抗剂调整至INR 2-3者DVT事件更多(OR 1.56;95%CI 1.14-2.14)。

核心结论

  • 相对于低分子量肝素每日一次方案,直接口服Xa抑制剂具有更有利的静脉血栓栓塞和出血风险特征,而维生素K拮抗剂特征较不利。
  • 其他药物的特征未显示更有利或更不利。
  • 临床医生在选择预防方案时应考虑这些特征。

研究设计与样本

  • 网络荟萃分析,从1990年1月至2016年6月发表的随机对照试验中提取12种预防方案的静脉血栓栓塞和出血信息。
  • 构建网络计算每种方案相对于低分子量肝素每日一次方案的相对风险。

主要发现

  • 相对于低分子量肝素每日一次方案,直接口服Xa抑制剂总深静脉血栓(无症状和有症状)风险最低(OR 0.45;95%CI 0.35-0.57),相当于每1000例患者减少53-139例DVT。
  • 维生素K拮抗剂调整至INR 2-3预测DVT事件增加56%(OR 1.56;95%CI 1.14-2.14)。
  • 阿司匹林表现相似(OR 0.80;95%CI 0.34-1.86),但样本量小无法得出确切结论。
  • 直接口服Xa抑制剂未导致显著更多出血(OR 1.21;95%CI 0.79-1.90)。
  • 相对于低分子量肝素每日一次方案,直接口服Xa抑制剂预防有症状DVT的效果高4倍(OR 0.25;95%CI 0.13-0.47)。

关键数值与推荐

  • 直接口服Xa抑制剂较低分子量肝素每日一次方案总DVT风险OR 0.45(95%CI 0.35-0.57)。
  • 维生素K拮抗剂调整至INR 2-3较低分子量肝素每日一次方案DVT风险OR 1.56(95%CI 1.14-2.14)。
  • 阿司匹林较低分子量肝素每日一次方案DVT风险OR 0.80(95%CI 0.34-1.86)。
  • 直接口服Xa抑制剂较低分子量肝素每日一次方案出血风险OR 1.21(95%CI 0.79-1.90)。
  • 直接口服Xa抑制剂较低分子量肝素每日一次方案有症状DVT风险OR 0.25(95%CI 0.13-0.47)。

临床怎么用

  • 临床医生在选择全髋和膝关节置换患者的静脉血栓栓塞预防方案时应考虑这些风险特征。

局限性

  • 阿司匹林相关样本量小,无法得出确切结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Despite trial data, guidelines have not endorsed direct oral Xa inhibitors above other options. We provide profiles of venous thromboembolism and hemorrhage risk for 12 options. Direct oral Xa inhibitors had a favorable profile compared with low-molecular-weight heparin. Other options did not have favorable profiles compared with low-molecular-weight heparin. SUMMARY: Background There are numerous trials and several meta-analyses comparing venous thromboembolism (VTE) prophylaxis options after total hip and knee replacement (THR and TKR). None have included simultaneous comparison of new with older options. Objective To measure simultaneously the relative risk of VTE and hemorrhage for 12 prophylaxis options. Methods We abstracted VTE and hemorrhage information from randomized controlled trials published between January 1990 and June 2016 comparing 12 prophylaxis options. We then constructed networks to compute the relative risk for each option, relative to once-daily dosing with low-molecular-weight heparin (LMWH) Low. Results Main: Relative to LMWH Low, direct oral Xa inhibitors had the lowest risk of total deep vein thrombosis (DVT)-asymptomatic and symptomatic- (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.35-0.57), translating to 53-139 fewer DVTs per 1000 patients. Vitamin K antagonists (VKAs) titrated to International Normalized Ratio [INR] 2-3 predicted 56% more DVT events (OR, 1.56; 95% CI, 1.14-2.14). Aspirin performed similarly (OR, 0.80; 95% CI, 0.34-1.86), although small numbers prohibit firm conclusions. Direct oral Xa inhibitors did not lead to significantly more bleeding (OR, 1.21; 95% CI, 0.79-1.90). Secondary: Relative to LMWH Low, direct oral Xa inhibitors prevented 4-fold more symptomatic DVTs (OR, 0.25; 95% CI, 0.13-0.47). Conclusions Relative to LMWH Low, direct oral Xa inhibitors had a more favorable profile of VTE and hemorrhage risk, whereas VKAs had a less favorable profile. The profile of other agents was not more or less favorable. Clinicians should consider these profiles when selecting prophylaxis options.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kapoor A, Ellis A, Shaffer N, et al. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost. 2017. PMID: 28102615. doi:10.1111/jth.13566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。